Mindestbestellung 120 EUR Kostenlose Lieferung ab 250 EUR Bereit zur Abholung dead drop: in 5 Min. abholen Kostenloser Versand ab 250 EUR Aktionen

Substanzen · Benzodiazepine und Thienodiazepine

Bromazolam

C17H13BrN4 CAS 71368-80-4 Nur für analytische Forschungszwecke — nicht für den menschlichen Verzehr
Bromazolam, Lehrillustration der Molekülstruktur
Lehrillustration der Molekülstruktur. Dies ist kein Produktfoto.
Bevorzugter Name
Bromazolam
IUPAC-Name
8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
CAS-Nummer der Stammverbindung (Referenz)
71368-80-4
Summenformel
C17H13BrN4
Molekulargewicht
353.2 g/mol
InChIKey
KCEIOBKDDQAYCM-UHFFFAOYSA-N
PubChem
CID 12562546
Quelle
PubChem
Geprüfte Synonyme und Katalogkürzel
XLI-269 8-Bromo-alprazolam

Passende Artikel im aktuellen Shop-Katalog

Geprüftes Pharmakologie- & Toxikologie-Dossier

Bromazolam

GABA-A Positive Allosteric Modulator (8-Bromo-alprazolam) Triazolobenzodiazepine
Geprüfte PubChem- & CAS-Identität C17H13BrN4 · CAS 71368-80-4 · CID 12562546
Kalibrierte Lieferform Präzisionstabletten · 1 Tablette = 1 mg
≥98 % analytische Reinheit geprüft 353.2 g/mol
WHO-, PubMed- & PubChem-Quellen 2 cited records

Rezeptor-Telemetrie & Wirkmechanismus

GABAₐ α₂/α₃ Anxiolysis & Myorelaxation High PAM
GABAₐ α₁ Hypnotic / Sedative Drive Moderate-High
GABAₐ α₅ Amnestic / Cognitive Modulation Moderate

Non-selective high-affinity PAM across alpha1, alpha2, alpha3, and alpha5 GABA-A receptor subtypes (structurally the 8-bromo analogue of alprazolam).

Biotransformation & Active Metabolites

Hepatic CYP3A4 hydroxylation to alpha-hydroxybromazolam and 4-hydroxybromazolam followed by glucuronidation.

Zeitliche Pharmakokinetik

GABA-A Positive Allosteric Modulator (8-Bromo-alprazolam) — 1 tablet = 1 mg sits at the light-to-common threshold; compared to Etizolam, Bromazolam is heavier on physical muscle relaxation and sedation and lasts 2–3 hours longer, while remaining significantly more forgiving per mg than Flualprazolam or Clonazolam.

  1. Onset 20–45 min
  2. Peak Window 1.5–3 h
  3. Total Window 6–10 h
  4. Residual / Half-Life 8–18 h residual sedation

1 tablet = 1 mg sits at the light-to-common threshold; compared to Etizolam, Bromazolam is heavier on physical muscle relaxation and sedation and lasts 2–3 hours longer, while remaining significantly more forgiving per mg than Flualprazolam or Clonazolam.

Quantitatives Wirkungsspektrum (Literaturdaten)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
0.5 mg
Cognitive & Sensory

Subtle threshold receptor activity (GABA-A Positive Allosteric Modulator (8-Bromo-alprazolam)).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
0.5–1 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
1–2 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
2–4 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
4–5+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Wechselwirkungsmatrix — Niemals kombinieren

Lebensgefahr — Niemals kombinieren

Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl)

Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.

Alcohol, GHB/GBL, and Barbiturates

Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.

Hohes Risiko — Vermeiden

Dissociatives (Ketamine, 2-FDCK, DCK, O-PCE, MXE)

Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.

Vorsicht / Abschwächung

CYP3A4 inhibitors (grapefruit juice, ketoconazole) & Stimulants

CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.

Isomeren- & Strukturvergleich

1 tablet = 1 mg sits at the light-to-common threshold; compared to Etizolam, Bromazolam is heavier on physical muscle relaxation and sedation and lasts 2–3 hours longer, while remaining significantly more forgiving per mg than Flualprazolam or Clonazolam.

Stabilität & Lagerung

Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.

Store sealed in a cool, dry, light-protected container away from humidity.

Cross-Tolerance & Dependence Profile

Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.

Analytische & toxikologische Monographie

Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; CAS 71368-80-4, PubChem CID 12562546) is a triazolobenzodiazepine reference compound (C17H13BrN4, 353.2 g/mol) classified pharmacologically as a GABA-A Positive Allosteric Modulator (8-Bromo-alprazolam). Non-selective high-affinity PAM across alpha1, alpha2, alpha3, and alpha5 GABA-A receptor subtypes (structurally the 8-bromo analogue of alprazolam). Hepatic CYP3A4 hydroxylation to alpha-hydroxybromazolam and 4-hydroxybromazolam followed by glucuronidation. In published observational and toxicological literature, threshold response is noted at 0.5 mg, light range at 0.5–1 mg, common reference range at 1–2 mg, strong intensity at 2–4 mg, and heavy/adverse territory at 4–5+ mg, with an onset of 20–45 min, peak window of 1.5–3 h, and total duration of 6–10 h (8–18 h residual sedation). 1 tablet = 1 mg sits at the light-to-common threshold; compared to Etizolam, Bromazolam is heavier on physical muscle relaxation and sedation and lasts 2–3 hours longer, while remaining significantly more forgiving per mg than Flualprazolam or Clonazolam. Critical contraindications include Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl), Alcohol, GHB/GBL, and Barbiturates.

Chemische Struktur und Molekülprofil

Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) ist eine Referenzverbindung aus der Stoffklasse Benzodiazepine und Thienodiazepine mit der Summenformel C17H13BrN4 und einer molaren Masse von 353.2 g/mol. Die Stammverbindung wird unter der CAS-Nummer 71368-80-4 sowie in der NCBI-PubChem-Datenbank unter CID 12562546 geführt (Standard-InChIKey: KCEIOBKDDQAYCM-UHFFFAOYSA-N).

Quellen

Referenztoxikologie und Sicherheitsprofil

Laut dokumentierten Referenzdaten (PubChem / PsychonautWiki, CC BY 4.0) gehört Bromazolam zur chemischen Klasse Benzodiazepine und Thienodiazepine. Diazepin-Referenzverbindung mit ausgeprägtem Risiko synergistischer Atemdepression in Kombination mit Opioiden, Alkohol oder anderen Sedativa. Beim Umgang im Labor sind geeignete persönliche Schutzausrüstung und das Sicherheitsdatenblatt (SDB) zu beachten.

Quellen

Analytischer Verwendungszweck und Laborhinweis

Dieses Datenblatt dient ausschließlich der chemischen, analytischen und toxikologischen Dokumentation. Das Material ist nicht für den menschlichen Verzehr bestimmt. Ein Forschungshinweis begründet keinen Rechtsstatus.

Quellen